<?xml version="1.0" encoding="utf-8"?><rss version="2.0" 
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
  xmlns:admin="http://webns.net/mvcb/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
<channel>
<title>dietrine</title>
<link>http://www.blogigo.com/dietrine</link>
<description></description>
<language>en</language>
<dc:creator>bellavita</dc:creator>
<dc:publisher>bellavita</dc:publisher>
<pubDate>Wed, 07 Nov 2007 21:37:06 +0100</pubDate>
<sy:updatePeriod>daily</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<item>
<title>dietrine</title>
<description> 
 1. In vivo effectiveness of a new commercial bean extract (Phase 2® ) prepared by Pharmachem Laboratories using normal human subjects. Protocol Five males and five females (ages 21 to 57) participated in a double-blind placebo-controlled study with normal subjects. Vinson, PhD, Donna M. Shuta, BS Department of Chemistry University of Scranton Background Amylase is a digestive tract enzyme, which breaks down starch into small units capable of being further degraded to glucose, which is used for fuel for normal metabolism and body homeostasis. Clinical use of inhibitors of amylase activity has widespread appeal because a controlled reduction of starch digestion could influence carbohydrate uptake in diabetes and obesity, the latter of which is a current problem with 20% of the US population. Of course obesity is also linked to a greater risk of diabetes. A search in the National Library of Medicine Database reveals that there are 1098 articles concerning amylase inhibition. 
 
 
About 15 years ago...</description>
<pubDate>Wed, 07 Nov 2007 21:37:06 +0100</pubDate>
<link>http://www.blogigo.com/dietrine/dietrine/1/</link>
<guid isPermaLink="true">http://www.blogigo.com/dietrine/dietrine/1/</guid>
</item></channel>	
</rss>